# Effect of Raltegravir in Patients With Acute Tropical Spastic Paraparesis - Human T-Lymphotropic Virus 1 Infection

> **NCT02655471** · EARLY_PHASE1 · COMPLETED · sponsor: **Universidad Peruana Cayetano Heredia** · enrollment: 10 (actual)

## Conditions studied

- HTLV-I Infections
- Tropical Spastic Paraparesis

## Interventions

- **DRUG:** "Raltegravir" and "Zidovudine"

## Key facts

- **NCT ID:** NCT02655471
- **Lead sponsor:** Universidad Peruana Cayetano Heredia
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-01
- **Primary completion:** 2019-03-15
- **Final completion:** 2019-03-15
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2019-05-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02655471

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02655471, "Effect of Raltegravir in Patients With Acute Tropical Spastic Paraparesis - Human T-Lymphotropic Virus 1 Infection". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02655471. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*